Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Clarifies ClinicalTrials.gov Postings; Listed As Sponsor Of 13 Studies

Executive Summary

Merck is enrolling patients in three type 2 diabetes trials - including pioglitazone and metformin add-on studies - for a late-stage investigational drug, according to the company's recently updated postings on the HHS-sponsored website ClinicalTrials.gov

You may also be interested in...



Sen. Baucus Urges More Comparative Research At Vioxx Hearing

The Vioxx withdrawal demonstrates the need for more comparative research on drugs, Sen. Max Baucus (D-N.M.) suggested in his questioning of witnesses at the Senate Finance Committee's hearing on Merck's withdrawal of the COX-2 inhibitor

Sen. Baucus Urges More Comparative Research At Vioxx Hearing

The Vioxx withdrawal demonstrates the need for more comparative research on drugs, Sen. Max Baucus (D-N.M.) suggested in his questioning of witnesses at the Senate Finance Committee's hearing on Merck's withdrawal of the COX-2 inhibitor

Antidepressant Manufacturer Trial Information Requested By Senate Cmte.

Antidepressant manufacturers have until Aug. 27 to submit information about pediatric clinical trials to the Senate Finance Committee

Related Content

Topics

UsernamePublicRestriction

Register

PS044477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel